A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
← catalyst calendarNCT05973487 · readout in 133 d
Sponsored by TScan Therapeutics, Inc. (industry) · TCRX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
840estimated
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-06 | actual | When the study began enrolling |
| Primary completion | 2026-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Head and Neck Cancer
- Cervical Cancer
- Non-small Cell Carcinoma
- Melanoma
- Ovarian Cancer
- Anogenital Cancers
- HPV - Anogenital Human Papilloma Virus Infection
- HPV-Related Cervical Carcinoma
- HPV-Related Carcinoma
- HPV-Related Squamous Cell Carcinoma
- HPV-Related Malignancy
- HPV-Related Adenocarcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- HPV-Related Adenosquamous Carcinoma
- HPV-Associated Vaginal Adenocarcinoma
- HPV-Related Endocervical Adenocarcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Verrucous Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- HPV Positive Rectal Squamous Cell Carcinoma
Interventions
- Biological: TSC-204-A0201
- Biological: TSC-204-C0702
- Biological: TSC-200-A0201
- Biological: TSC-204-A0201 + TSC-204-C0702
- Biological: TSC-204-A0201 + TSC-200-A0201
- Biological: TSC-204-C0702 + TSC-200-A0201
- Biological: TSC-204-A0201 + TSC-203-A0201
- Biological: TSC-204-C0702 + TSC-203-A0201
- Biological: TSC-200-A0201 + TSC-203-A0201
- Biological: TSC-203-A0201
- Biological: TSC-204-A0101
- Biological: TSC-201-B0702
- Biological: TSC-204-A0201 + TSC-204-A0101
- Biological: TSC-204-A0201 + TSC-201-B0702
- Biological: TSC-204-C0702 + TSC-204-A0101
- Biological: TSC-204-C0702 + TSC-201-B0702
- Biological: TSC-200-A0201 + TSC-204-A0101
- Biological: TSC-200-A0201 + TSC-201-B0702
- Biological: TSC-203-A0201 + TSC-204-A0101
- Biological: TSC-203-A0201 + TSC-201-B0702
- Biological: TSC-202-A0201
- Biological: TSC-204-A0201 + TSC-202-A0201
- Biological: TSC-204-C0702 + TSC-202-A0201
- Biological: TSC-200-A0201 + TSC-202-A0201
- Biological: TSC-203-A0201 + TSC-202-A0201
- Biological: TSC-204-A0101 + TSC-202-A0201
- Biological: TSC-201-B0702 + TSC-202-A0201
Primary outcomes
what the primary-completion date above is the date OFEvaluate the safety of monotherapy and T- Plex combination TCR-Ts
measured 28 days
Determine the recommended phase 2 dose of monotherapy and T- Plex combination TCR-Ts
measured Up to 12 months
Permalink · TCRX's whole pipeline · Catalyst calendar · Every registered study · What changed